AVITA Medical, Inc. (RCEL)
15.63
-0.57
(-3.52%)
USD |
NASDAQ |
Nov 13, 16:00
15.60
-0.03
(-0.19%)
After-Hours: 19:59
AVITA Medical Shareholders Equity (Quarterly) : -31.04M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -31.04M |
| June 30, 2026 | -27.84M |
| March 31, 2026 | -23.17M |
| December 31, 2025 | -16.65M |
| September 30, 2025 | -6.666M |
| June 30, 2025 | -12.89M |
| March 31, 2025 | -4.571M |
| December 31, 2024 | 4.499M |
| September 30, 2024 | 12.23M |
| June 30, 2024 | 23.92M |
| March 31, 2024 | 32.57M |
| December 31, 2023 | 49.06M |
| Date | Value |
|---|---|
| September 30, 2023 | 62.98M |
| June 30, 2023 | 68.65M |
| March 31, 2023 | 77.56M |
| December 31, 2022 | 84.74M |
| September 30, 2022 | 87.99M |
| June 30, 2022 | 92.56M |
| March 31, 2022 | 97.82M |
| June 30, 2021 | 115.66M |
| March 31, 2021 | 118.94M |
| December 31, 2020 | 59.60M |
| September 30, 2020 | 65.49M |
| June 30, 2020 | 72.40M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | 812.66M |
| Halozyme Therapeutics, Inc. | -55.24M |
| Agenus, Inc. | -105.37M |
| Amgen, Inc. | 14.35B |
| Fate Therapeutics, Inc. | 133.03M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 46.79M |
| Total Liabilities (Quarterly) | 77.83M |
| Debt to Equity Ratio | -1.519 |
| Current Ratio | 1.201 |
| Net Debt Paydown Yield | -0.14% |